4 recruiting, 3 completed, 2 active not recruiting, 2 unknown. 13 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 4, Completed 3, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Cardiogenic Shock: new trials by email Literature Review of Cardiogenic Shock trials Research Report on Cardiogenic Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock Methylprednisone, Standard of Care (SOC) - Cardiogenic Shock, Heart Failure | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 30 | 2026-10-01 | 2026-08-13 |
| Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock istaroxime, placebo - Cardiogenic Shock | Phase 2 / Phase 3 | Recruiting | Seismic Pharmaceuticals Operations LLC | 600 | 2026-09-09 | 2026-09-23 |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System Cardiohelp device (VA-ECMO), Heparin, Bivalirudin - Heart Failure, Cardiogenic Shock | Phase 2 | Recruiting | Stanford University | 50 | 2025-04-15 | 2026-08-10 |
| Physiology of Unloading VA ECMO Trial IABP - Cardiogenic Shock | Phase 2 | Recruiting | University of Utah | 104 | 2024-10-02 | 2026-04-30 |
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Istaroxime, Placebo - Cardiogenic Shock | Phase 1 / Phase 2 | Active not recruiting | Windtree Therapeutics | 20 | 2024-06-01 | 2025-08-20 |
| REMAP ECMO - Beta Receptor Modulation Trial Esmolol - Heart Failure, Cardiogenic Shock | Phase 2 | Unknown | Erasmus Medical Center | 20 | 2024-06-01 | 2024-07-26 |
| Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO Cangrelor - Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | Phase 2 | Recruiting | IRCCS San Raffaele | 50 | 2024-04-01 | 2025-01-27 |
| Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock Tocilizumab, Dobutamine, NaCl 0.9% - Acute Myocardial Infarction, Cardiogenic Shock | Phase 2 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 100 | 2022-03-13 | 2025-07-17 |
| The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Istaroxime, Placebo - Cardiogenic Shock | Phase 2 | Completed | Windtree Therapeutics | 90 | 2020-09-28 | 2025-02-04 |
| Adrecizumab in Cardiogenic Shock Adrecizumab, Placebo - Cardiogenic Shock, Endothelial Dysfunction | Phase 2 / Phase 3 | Completed | Dr. med. Mahir Karakas | 150 | 2019-04-04 | 2021-10-08 |
| Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock adrenaline - Cardiogenic Shock | Phase 2 | Completed | Niguarda Hospital | 24 | 2015-10-01 | 2021-07-26 |
| HEROIC (Heparin Requirement in Counterpulsation) Heparin, Without Heparin - Cardiogenic Shock | Phase 2 | Terminated | Corewell Health East | 46 | 2006-01-01 | 2017-05-19 |
| Levosimendan Versus Dobutamine in Shock Patients Levosimendan, Dobutamine - Cardiogenic Shock, Septic Shock | Phase 2 / Phase 3 | Unknown | Wentworth Area Health Services | 40 | 2004-10-01 | 2005-06-24 |
Shock, Cardiogenic (13) · Heart Failure (5) · Inflammation (2) · Acute Coronary Syndrome (1) · Cardiomyopathies (1) · Heart Defects, Congenital (1) · Hemorrhage (1) · ST Elevation Myocardial Infarction (1) · Sepsis (1) · Shock (1) · Shock, Septic (1)
Cardiovascular Diseases (13) · Heart Diseases (13) · Infarction (13) · Ischemia (13) · Myocardial Infarction (13) · Myocardial Ischemia (13) · Necrosis (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Vascular Diseases (13) · Shock (12) · Cardiovascular Abnormalities (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Infections (1)
Istaroxime (3) · Dobutamine (2) · Heparin (2) · Sodium Chloride (2) · Epinephrine (1) · Lactic Acid (1) · Simendan (1) · Standard of Care (1) · bivalirudin (1) · cangrelor (1) · enibarcimab (1) · esmolol (1) · tocilizumab (1)
Windtree Therapeutics (2) · Brigham and Women's Hospital (1) · Copenhagen University Hospital, Rigshospitalet (1) · Corewell Health East (1) · Dr. med. Mahir Karakas (1) · Erasmus Medical Center (1) · IRCCS San Raffaele (1) · Niguarda Hospital (1) · Seismic Pharmaceuticals Operations LLC (1) · Stanford University (1) · University of Utah (1) · Wentworth Area Health Services (1)
United States (6) · Italy (4) · Argentina (2) · Poland (2) · Armenia (1) · Australia (1) · Denmark (1) · Germany (1) · Israel (1) · Netherlands (1)
Caroline Ozment, MD (1) · Christiaan L. Meuwese (1) · Gabe Coitler (1) · Justin Trivax, M.D. (1) · Lynn Sleeper, ScD (1) · Mahir Karakas, MD, MBA (1) · Marco Metra, MD (1) · Martin Frydland, MD, PhD (1) · Steven G Simonson, MD (1)